Holen Sie sich die Stockscreener-App
1.67
1.83%
0.03
Handel nachbörslich:
1.65
-0.02
-1.20%
Schlusskurs vom Vortag:
$1.64
Offen:
$1.66
24-Stunden-Volumen:
462.12K
Relative Volume:
0.49
Marktkapitalisierung:
$64.70M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-77.91M
KGV:
-0.8253
EPS:
-2.0234
Netto-Cashflow:
$-65.33M
1W Leistung:
+9.15%
1M Leistung:
+3.09%
6M Leistung:
-11.64%
1J Leistung:
-22.33%
1-Tages-Spanne:
$1.59
$1.69
1-Wochen-Bereich:
$1.44
$1.69
52-Wochen-Spanne:
$1.05
$3.56
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Firmenname
Acrivon Therapeutics Inc
Sektor
Branche
Telefon
617-207-8979
Adresse
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.67 | 63.54M | 0 | -77.91M | -65.33M | -2.0234 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-05 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-31 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-12-15 | Fortgesetzt | Jefferies | Buy |
| 2023-10-05 | Eingeleitet | Maxim Group | Buy |
| 2023-06-02 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-04-27 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2023-04-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-12-12 | Eingeleitet | Jefferies | Buy |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Acrivon Therapeutics Inc Aktie (ACRV) Neueste Nachrichten
Acrivon Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Portfolio Update: What is Acrivon Therapeutics Incs 5 year growth outlookStop Loss & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Acrivon Therapeutics Inc. (ACRV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Market Catalysts: Will Acrivon Therapeutics Inc benefit from rate cuts2026 Drop Watch & Daily Stock Momentum Reports - baoquankhu1.vn
VIX Spike: Is Acrivon Therapeutics Inc gaining market shareWeekly Trade Summary & Low Risk Investment Opportunities - baoquankhu1.vn
Published on: 2026-04-07 20:07:09 - baoquankhu1.vn
Portfolio Shifts: Can Acrivon Therapeutics Inc expand into new markets2026 Selloffs & Smart Allocation Stock Reports - baoquankhu1.vn
Aug Intraday: Is Acrivon Therapeutics Inc a good ESG investmentQuarterly Profit Review & Low Risk High Win Rate Picks - baoquankhu1.vn
ACRV Stock Price, Quote & Chart | ACRIVON THERAPEUTICS INC (NASDAQ:ACRV) - ChartMill
AI Stocks: Can Acrivon Therapeutics Inc ride the EV wave2026 Earnings Impact & Community Trade Idea Sharing Platform - baoquankhu1.vn
We're Keeping An Eye On Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate - Sahm
Citizens reiterates Acrivon Therapeutics stock rating on endometrial cancer trial progress - Investing.com Australia
Citizens reiterates Acrivon Therapeutics stock rating on endometrial cancer trial progress By Investing.com - Investing.com South Africa
[SCHEDULE 13D/A] Acrivon Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan
Research Analysts Set Expectations for ACRV Q1 Earnings - marketbeat.com
If You Invested $1,000 in Acrivon Therapeutics, Inc. (ACRV) - Stock Titan
ACRV Technical Analysis & Stock Price Forecast - Intellectia AI
Aug EndMonth: What is Acrivon Therapeutics Incs 5 year growth outlook2026 Levels & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Form 4 Acrivon Therapeutics Inc For: 4 March By Investing.com - Investing.com Australia
Acrivon Therapeutics (NASDAQ:ACRV) Releases Earnings Results, Meets Estimates - MarketBeat
Oppenheimer reiterates Acrivon stock rating on endometrial cancer focus - Investing.com UK
Oppenheimer reiterates Acrivon stock rating on endometrial cancer focus By Investing.com - Investing.com Canada
Acrivon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Acrivon Highlights Positive ACR-368 Data and 2025 Results - TipRanks
ACRV: 52% response rate in serous endometrial cancer and robust cash reserves support ongoing growth - TradingView
BRIEF-Acrivon Therapeutics, Inc Q4 Income From Operations USD -20.116 Million - tradingview.com
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Acrivon Therapeutics (ACRV) posts 2025 results, 52% ACR-368 response and $118.6M cash - Stock Titan
Cancer drug study posts 52% response as Acrivon adds new arm - Stock Titan
Acrivon Therapeutics 10-K: $0 Revenue, $(0.00) EPS, $77.9M Net Loss - TradingView
ACRV: Net loss narrowed to $77.9M in 2025; cash runway extends into Q2 2027 - TradingView
Oncology pipeline and AP3 proteomics strategy at Acrivon (NASDAQ: ACRV) - Stock Titan
ACRV Q4'25 Earnings: revenue estimate is 166.29K USD - tradingview.com
Acrivon Therapeutics (ACRV) Projected to Post Earnings on Thursday - MarketBeat
Acrivon Therapeutics, Inc. (ACRV) upgraded to buy: Here's why - MSN
Acrivon Therapeutics to Present Pre-Clinical Data on ACR-368 and ACR-2316 Synergy with ADCs and Immune Checkpoint Inhibitors at 2026 AACR Annual Meeting - geneonline.com
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at - GlobeNewswire
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors - chartmill.com
Dow Update: Will Acrivon Therapeutics Inc benefit from green energy policiesTrade Entry Summary & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Cancer drug combo clears tumors in mice in Acrivon study - Stock Titan
EPS Watch: Is Acrivon Therapeutics Inc gaining market shareWatch List & Consistent Return Investment Signals - baoquankhu1.vn
Acrivon Therapeutics (ACRV) Stock Analysis Report | Financials & Insights - Benzinga Japan
Acrivon Therapeutics shares slide sharply following mixed oncology trial update - MSN
Gains Report: What is Acrivon Therapeutics Incs 5 year growth outlookWeekly Risk Summary & Real-Time Volume Analysis - baoquankhu1.vn
Acrivon Therapeutics, Inc. (ACRV) Presents at TD Cowen 46th Annual Health Care ConferenceSlideshow - Seeking Alpha
Acrivon Therapeutics, Inc. (ACRV) Presents at ESGO 27th Annual Congress 2026Slideshow - Seeking Alpha
Acrivon Therapeutics Highlights ACR-368’s ~50% Response in Serous Endometrial Cancer at TD Cowen Conf. - Defense World
Acrivon Therapeutics (ACRV) CAO awarded 31,900 stock options at $0.00 strike - Stock Titan
Finanzdaten der Acrivon Therapeutics Inc-Aktie (ACRV)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):